Literature DB >> 12417566

In vivo regulation of plasminogen function by plasma carboxypeptidase B.

Carmen M Swaisgood1, Detlef Schmitt, Dan Eaton, Edward F Plow.   

Abstract

The major functions of plasminogen (Plg) in fibrinolysis and cell migration depend on its binding to carboxy-terminal lysyl residues. The ability of plasma carboxypeptidase B (pCPB) to remove these residues suggests that it may act as a suppressor of these Plg functions. To evaluate this role of pCPB in vivo, homozygote pCPB-deficient mice were generated by homologous recombination, and the resulting pCPB(-/-) mice, which were viable and healthy, were mated to Plg(-/-) mice. Plg(+/-) mice show intermediate levels of fibrinolysis and cell migration compared with Plg wild-type and deficient mice, reflecting the intermediate levels of the Plg antigen in their plasma. Differences in Plg-dependent functions between pCPB(+/+), pCPB(+/-), and pCPB(-/-) mice were then analyzed in a Plg(+/-) background. In a pulmonary clot lysis model, fibrinolysis was significantly increased in mice with partial (pCPB(+/-)) or total absence (pCPB(-/-)) of pCPB compared with their wild-type counterparts (pCPB(+/+)). In a thioglycollate model of peritoneal inflammation, leukocyte migration at 72 hours increased significantly in Plg(+/-)/pCPB(+/-) and Plg(+/-)/pCPB(-/-) compared with their wild-type counterparts. These studies demonstrate a definitive role of pCPB as a modulator of the pivotal functions of Plg in fibrinolysis and cell migration in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417566      PMCID: PMC151605          DOI: 10.1172/JCI15082

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.

Authors:  M Nagashima; M Werner; M Wang; L Zhao; D R Light; R Pagila; J Morser; P Verhallen
Journal:  Thromb Res       Date:  2000-05-15       Impact factor: 3.944

2.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

Authors:  N H van Tilburg; F R Rosendaal; R M Bertina
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

3.  Proteolytic activation of purified human procarboxypeptidase U.

Authors:  K A Schatteman; F J Goossens; S S Scharpé; D F Hendriks
Journal:  Clin Chim Acta       Date:  2000-02-25       Impact factor: 3.786

4.  Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.

Authors:  E Creemers; J Cleutjens; J Smits; S Heymans; L Moons; D Collen; M Daemen; P Carmeliet
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

5.  Characterization of mouse thrombin-activatable fibrinolysis inhibitor.

Authors:  P F Marx; G T Wagenaar; A Reijerkerk; M J Tiekstra; A G van Rossum; M F Gebbink; J C Meijers
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

6.  Plasma TAFI antigen variations in healthy subjects.

Authors:  P Chetaille; M C Alessi; D Kouassi; P E Morange; I Juhan-Vague
Journal:  Thromb Haemost       Date:  2000-06       Impact factor: 5.249

7.  The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.

Authors:  C M Swaisgood; E L French; C Noga; R H Simon; V A Ploplis
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

8.  A novel approach to arterial thrombolysis.

Authors:  P Klement; P Liao; L Bajzar
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

9.  Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.

Authors:  T H Bugge; M J Flick; C C Daugherty; J L Degen
Journal:  Genes Dev       Date:  1995-04-01       Impact factor: 11.361

10.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  30 in total

1.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.

Authors:  Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.

Authors:  Pavel Bouchal; Monika Dvořáková; Theodoros Roumeliotis; Zbyněk Bortlíček; Ivana Ihnatová; Iva Procházková; Jenny T C Ho; Josef Maryáš; Hana Imrichová; Eva Budinská; Rostislav Vyzula; Spiros D Garbis; Bořivoj Vojtěšek; Rudolf Nenutil
Journal:  Mol Cell Proteomics       Date:  2015-04-22       Impact factor: 5.911

Review 3.  Functions of the plasminogen receptor Plg-RKT.

Authors:  Lindsey A Miles; Juliana P Vago; Lirlândia P Sousa; Robert J Parmer
Journal:  J Thromb Haemost       Date:  2020-08-19       Impact factor: 5.824

4.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

5.  Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT.

Authors:  Shahrzad Lighvani; Nagyung Baik; Jenna E Diggs; Sophia Khaldoyanidi; Robert J Parmer; Lindsey A Miles
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

Review 6.  New insights into the role of Plg-RKT in macrophage recruitment.

Authors:  Lindsey A Miles; Shahrzad Lighvani; Nagyung Baik; Caitlin M Parmer; Sophia Khaldoyanidi; Barbara M Mueller; Robert J Parmer
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

Review 7.  Plasminogen receptors: the first quarter century.

Authors:  Lindsey A Miles; Robert J Parmer
Journal:  Semin Thromb Hemost       Date:  2013-03-26       Impact factor: 4.180

8.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.

Authors:  Peter Kraft; Tobias Schwarz; Joost C M Meijers; Guido Stoll; Christoph Kleinschnitz
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

9.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

Review 10.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.